This stemness gene suppression suggests the possibility of using a continuum of Top2 catalytic inhibitors in the progression of PCa disease with the synergism of an EZH2 degrader in AR-dependent PCa cells and EZH2 catalytic inhibitors in NEPC tumor cells. This evidence concerns the gene TOP2A and posterior cortical atrophy.